News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Top Technical Advances in 2017
Shawna Williams | Dec 24, 2017
The year’s most impressive achievements include new methods to extend CRISPR editing, patch-clamp neurons hands-free, and analyze the contents of live cells.
CRISPR Proves Promising for Treating ALS in Mice
Katarina Zimmer | Dec 21, 2017
The gene-editing tool was effective in disabling a defective gene responsible for some forms of amyotrophic lateral sclerosis.
CRISPR to Debut in Clinical Trials
Diana Kwon | Dec 14, 2017
The first industry-sponsored CRISPR therapy is slated to be tested in humans in 2018.
2017 Top 10 Innovations
Staff | Dec 1, 2017
From single-cell analysis to whole-genome sequencing, this year's best new products shine on many levels.
RNA Editing Possible with CRISPR-Cas13
Ruth Williams | Oct 25, 2017
Scientists extend the capabilities of the CRISPR-Cas system to include precise manipulations of RNA sequences in human cells.
Base Editing Now Able to Convert Adenine-Thymine to Guanine-Cytosine
Catherine Offord | Oct 25, 2017
With the arrival of a new class of single-nucleotide editors, researchers can target the most common type of pathogenic SNP in humans.
Image of the Day: CRISPR on a Mouse Canvas
Staff, The Scientist Staff | Oct 25, 2017
Scientists are using CRISPR-Cas9 technology to tag and explore specific sets of neurons in mice, in one of the first steps towards building a comprehensive atlas of brain circuitry.
Gene Drive Limitations
Jef Akst | Oct 9, 2017
In lab populations of genetically engineered mosquitoes, mutations arose that blocked the gene drive’s spread and restored female fertility.
CRISPR System Targets RNA in Mammalian Cells
Anna Azvolinsky | Oct 4, 2017
Researchers engineer bacterial CRISPR-Cas13 to knock down RNA in mammalian cells.
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.